(l7)
OpenAs .pdf
See at PubMed
Time for integrating clinical, lifestyle and molecular data to predict drug responses - Authors' reply.
Pottegård A, Friis S, Christensen Rd, Habel LA, Gagne JJ, Hallas J.
EBioMedicine. 2016 May

(l6)
OpenAs .pdf
See at PubMed
Re: Pregabalin prescriptions in the United Kingdom - a drug utilisation study of The Health Improvement Network (THIN) primary care database by Asomaning et al.
Pottegård A, Tjäderborn M, Schjerning O, Nielsen J, Damkier P, Bodén R.
Int J Clin Pract. 2016 Aug

(l5)
OpenAs .pdf
See at PubMed
Inconsistencies in reporting of renal elimination among NOACs: the case of apixaban
Hellfritzsch M, Damkier P, Pottegård A, Grønlykke T, Grove EL.
Pharmacoepidemiol Drug Saf. 2016 Mar

(l4)
See at PubMed
Re: In utero SSRI exposure and risk of clubfoot
Henriksen DP, Pottegård A, Jimenez-Solem E, Damkier P.
Epidemiology. 2015 May;26(3):e34-5

(l3)
OpenAs .pdf
See at PubMed
Pregnancy and paracetamol: Methodological considerations on the study of associations between in utero exposure to drugs and childhood neurodevelopment
Damkier P, Pottegård A, Christensen RD, Hallas J
Basic Clin Pharmacol Toxicol. 2015 Jan;116(1):2-5.

(l2)
OpenAs .pdf
See at PubMed
Reply to "Evidence for harm, comment on..." by Kripke & Langer
Pottegård A, Friis S, Andersen M, Hallas J.
Br J Clin Pharmacol. 2014 Jul; 78(1): 188-9

(l1)
OpenAs .pdf
Hypnotics' association with mortality or cancer: bias related to the study design and analysis
Andersen M, Pottegård A, Friis S, Hallas J.


CONTACT INFORMATION

EMAIL ADDRESS
apottegaard@health.sdu.dk

PHONE NUMBER
+45 28913340


HOME ADDRESS
Anton Pottegaard
Lysalleen 7F
4000 Roskilde
DENMARK